Ketamine : friend or foe?

Steyn, Nicolene

Please note that UPSpace will be unavailable from Friday, 2 May at 18:00 (South African Time) until Sunday, 4 May at 20:00 due to scheduled system upgrades. We apologise for any inconvenience this may cause and appreciate your understanding.

Show simple item record

dc.contributor.author	Steyn, Nicolene
dc.date.accessioned	2023-05-18T08:31:54Z
dc.date.available	2023-05-18T08:31:54Z
dc.date.issued	2023-09
dc.description.abstract	Ketamine, a dissociative anaesthetic drug, acts on the central nervous system (CNS) primarily through antagonism of the n-methyl-d-aspartate (NMDA) receptor. Methods of administration include intravenous, intramuscular, snorting and smoking. Intranasal use, which has a very rapid onset of action, is common among recreational users.	en_US
dc.description.department	Chemical Pathology	en_US
dc.description.librarian	hj2023	en_US
dc.description.uri	http://jcp.bmj.com	en_US
dc.identifier.citation	Steyn, N. 2023, 'Ketamine: friend or foe?', Journal of Clinical Pathology, vol. 76, pp. 581, doi: 10.1136/jclinpath-2021-207586.	en_US
dc.identifier.issn	0021-9746 (print)
dc.identifier.issn	1472-4146 (online)
dc.identifier.other	10.1136/jclinpath-2021-207586
dc.identifier.uri	http://hdl.handle.net/2263/90738
dc.language.iso	en	en_US
dc.publisher	BMJ Publishing Group	en_US
dc.rights	© Author(s) (or their employer(s)) 2023. No commercial re-use.	en_US
dc.subject	Ketamine	en_US
dc.subject	Dissociative anaesthetic drug	en_US
dc.subject	Central nervous system (CNS)	en_US
dc.subject	N-methyl-d-aspartate (NMDA)	en_US
dc.subject.other	Health sciences articles SDG-03
dc.subject.other	SDG-03: Good health and well-being
dc.title	Ketamine : friend or foe?	en_US
dc.type	Postprint Article	en_US